Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Indirect comparison of bendamustine-rituximab and R-CHOP with rituximab maintenance in first-line treatment of elderly Mantle Cell Lymphoma: Data from the enrich trial

Lexy Sorrell, Toby Eyre, Mats Jerkeman, Simon Rule, Dave Wright, Cathy Burton, Mark Bishton, Andrew Davies, Christopher McNamara, Kristina Sonnevi, Jon Riise, Christian Poulsen, Ingemar Lagerlöf, Ingrid Glimelius, Karin Wader, David Lewis

Blood (2025) 146 (Supplement 1): 1822.

https://doi.org/10.1182/blood-2025-1822

Published: 2025

Journal Articles

Conventional quality-of-life data analyses underestimate gains in Mantle Cell Lymphoma clinical trials: A re-examination of enrich study data

Blood (2025) 146 (Supplement 1): 1804.

https://doi.org/10.1182/blood-2025-1804

Published: 2025

Journal Articles

Plasma protein ADAMTS8 as a minimally invasive favorable prognostic biomarker in mantle cell lymphoma

Ingrid Glimelius, Tove Selvin, Mattias Berglund, Rasmus Rask Kragh Jørgensen, Patrick Nylund, Karin Wader, Annika Pasanen, Won Seog Kim, Jacob Christensen, Daniel Molin, Gunilla Enblad, Mats Hellström, Mats Jerkeman

Blood (2025) 146 (Supplement 1): 3576.

https://doi.org/10.1182/blood-2025-3576

Published: 2025

Journal Articles

Risk of bleeding in 15,495 patients with myeloproliferative neoplasms by treatment type and thrombotic history

Stefanie Antonilli, Anna Ravn Landtblom, Malin Hultcrantz, Nurgul Batyrbekova, Ingrid Glimelius, Matthew Maurer, Therese Andersson, Caroline Dietrich

Blood (2025) 146 (Supplement 1): 5568.

https://doi.org/10.1182/blood-2025-5568

Published: 2025

Journal Articles

Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich

Blood (2024) 144 (Supplement 1): 235.

https://doi.org/10.1182/blood-2024-199710

Published: 2024

Journal Articles

Incidence of Infections and Survival Outcomes in Patients with Multiple Myeloma and Chronic Lymphocytic Leukemia in Sweden: A Nationwide Population-Based Study of More Than 15,000 Patients

Ingrid Glimelius, Love Tätting, Jonatan Freilich, Marta Natalia Stelmaszuk, Qian Yang, Anna Deleskog, Sigurdur Y Kristinsson

Blood (2024) 144 (Supplement 1): 1857.

https://doi.org/10.1182/blood-2024-193619

Published: 2024

Journal Articles

Survival in Mantle Cell Lymphoma Patients with a Second Primary Malignancy

Kossi D Abalo, Trine Trap, Joachim Baech, Sara Ekberg, Simon Pahnke, Alexandra Albertsson-Lindblad, Karin Ekstroem Smedby, Mats Jerkeman, Peter Brown, Thomas Stauffer Larsen, Kirsten Gronbaek, Tarec Christoffer El-Galaly, Ingrid Glimelius

Blood (2024) 144 (Supplement 1): 1638.

https://doi.org/10.1182/blood-2024-206964

Published: 2024

Journal Articles

Acalabrutinib and Rituximab in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma Including a Matched Population-Based External Comparator- the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) Phase II Trial

Mats Jerkeman, Karin Fahl Wader, Ingrid Glimelius, Annika Pasanen, Won Seog Kim, Louise Krüger Hansen, Jon Riise, Martin Hutchings, Hashim Hussein Elhussein, Carsten Utoft Niemann, Rasmus Rask Kragh Jørgensen, Tarec Christoffer El-Galaly, Mats Ehinger, Klaus Beiske, Rose-Marie Amini, Michael Boe Møller, Marja-Liisa Karjalainen-Lindsberg, Jacob Haaber Christensen

Blood (2024) 144 (Supplement 1): 747.

https://doi.org/10.1182/blood-2024-192939

Published: 2024

Journal Articles

Zilovertamab Vedotin Monotherapy for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort a of the Multicenter, Open-Label, Phase 2 Waveline-006 Study

Ingrid Glimelius, Won Seog Kim, Ewa Paszkiewicz-Kozik, Daniel Ernst, Reid W. Merryman, Claudia Moreira, Sanfang Tu, Yixin Ren, Katherine Ryland, Uzor C. Ogbu, Pier Luigi Zinzani

Blood (2024) 144 (Supplement 1): 4405.

https://doi.org/10.1182/blood-2024-205897

Published: 2024

Journal Articles

Plasma Proteomic Profiling Identifies Prognostic Biomarkers in Mantle Cell Lymphoma

Tove Selvin, Patrick Nylund, Ann-Marie Ly, Anna Nikkarinen, Mattias Berglund, Kossi D Abalo, Daniel Molin, Gunilla Enblad, Peter Hollander, Mats Hellström, Ingrid Glimelius

Blood (2024) 144 (Supplement 1): 1623.

https://doi.org/10.1182/blood-2024-209805

Published: 2024

Journal Articles

Rule-Based Machine Learning Analysis of the Blood Proteome Identifies MCL Patients with High Risk of Early Disease Progression

Patrick Nylund, Kossi D Abalo, Saima Zubair, Eirini Voutsinou, Tove Selvin, Ann-Marie Ly, Anna Nikkarinen, Mattias Berglund, Daniel Molin, Gunilla Enblad, Peter Hollander, Mats Hellström, Ingrid Glimelius

Blood (2024) 144 (Supplement 1): 2995.

https://doi.org/10.1182/blood-2024-204816

Published: 2024

Journal Articles

Timing of Disease Progression and Impact on Survival in Mantle Cell Lymphoma: A Novel Illness-Death Model Study from the Swedish Mclcomplete Project

Sara Ekberg, Ingrid Glimelius, Alexandra Albertsson-Lindblad, Karin Ekstroem Smedby, Mats Jerkeman, Caroline E Dietrich

Blood (2024) 144 (Supplement 1): 3014.

https://doi.org/10.1182/blood-2024-200664

Published: 2024

Journal Articles

Zilovertamab Vedotin in Combination with Nemtabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort C of the Open-Label, Phase 2 Waveline-006 Study

Ewa Paszkiewicz-Kozik, Claudia Moreira, Mehmet Turgut, Marcelo Garrido, Ingrid Glimelius, Seung Tae Lee, Yazeed Sawalha, Yixin Ren, Katherine Ryland, Uzor C. Ogbu, Diego Villa

Blood (2024) 144 (Supplement 1): 3025.

https://doi.org/10.1182/blood-2024-205985

Published: 2024

Journal Articles

Plasma Proteomics Differentiates between Patients with B-Cell Lymphomas

Haris Babačić, Nashif Mahruf Chowdhury, Mattias Berglund, Jamileh Hashemi, Jeremia Collin, Emma Pettersson, Ann-Marie Ly, Anna Nikkarinen, Gunilla Enblad, Daniel Molin, Ingrid Glimelius, Maria Pernemalm, Mats Hellström

Blood (2024) 144 (Supplement 1): 4370.

https://doi.org/10.1182/blood-2024-204083

Published: 2024

Journal Articles

Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study

Blood (2024) 144 (9): 1001–1009.

https://doi.org/10.1182/blood.2023023525

Published: 2024

Includes: Supplemental data

Journal Articles

Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase Ib-II Trial

Mats Jerkeman, Arne Kolstad, Martin Hutchings, Annika Pasanen, Leo Meriranta, Carsten Utoft Niemann, Rasmus Rask Kragh Jørgensen, Tarec Christoffer Christoffer El-Galaly, Jon Riise, Sirpa Leppä, Jacob Haaber Christensen, Karin Fahl Wader, Ingrid Glimelius

Blood (2022) 140 (Supplement 1): 184–185.

https://doi.org/10.1182/blood-2022-155654

Published: 2022

Journal Articles

Treatment-Related Circulatory Diseases and Mortality in Hodgkin Lymphoma Patients Using Multi-State Modelling and Relative Survival

Joachim Baech, Lasse Hjort Jakobsen, Tarec Christoffer Christoffer El-Galaly, Daniel Molin, Ingrid Glimelius, Joshua P.P. Entrop, Michael Crowther, Karin Ekstroem Smedby, Sandra Eloranta, Caroline E. Weibull

Blood (2022) 140 (Supplement 1): 9411–9412.

https://doi.org/10.1182/blood-2022-157279

Published: 2022

Journal Articles

Reproduktiv Patterns Among Non-Hodgkin Lymphoma Survivors By Subtype in Sweden, Denmark and Norway

Joshua P.P. Entrop, Caroline E. Weibull, Karin E. Smedby, Lasse Hjort Jakobsen, Andreas K. Oevlisen, Ingrid Glimelius, Anna Marklund, Thomas S. Larsen, Harald Holte, Alexander Fosså, Knut B. Smeland, Tarec Christoffer Christoffer El-Galaly, Sandra Eloranta

Blood (2022) 140 (Supplement 1): 1079–1081.

https://doi.org/10.1182/blood-2022-155919

Published: 2022

Journal Articles

Late Effects after Treatment in Mantle Cell Lymphoma: No Difference By Intensity of First-Line Regimens with or without Autologous Stem Cell Transplantation

Sara Ekberg, Karin E. Smedby, Alexandra Albertsson-Lindblad, Mats Jerkeman, Caroline Weibull, Ingrid Glimelius

Blood (2021) 138 (Supplement 1): 1344.

https://doi.org/10.1182/blood-2021-145450

Published: 2021

Journal Articles

Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - Data from the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase I Trial: Stopping Treatment in Molecular Remission Is Feasible

Mats Jerkeman, MD PhD, Arne Kolstad, MD PhD, Carsten Utoft Niemann, MD PhD, Kirsten Groenbaek, MD DMSc, Martin Hutchings, MD PhD, Annika Pasanen, MD PhD, Sara Ekberg, Karin Fahl Wader, MD PhD, Ingrid Glimelius, MD PhD

Blood (2020) 136 (Supplement 1): 15.

https://doi.org/10.1182/blood-2020-133273

Published: 2020

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Indirect comparison of bendamustine-rituximab and R-CHOP with rituximab maintenance in first-line treatment of elderly Mantle Cell Lymphoma: Data from the enrich trial

Conventional quality-of-life data analyses underestimate gains in Mantle Cell Lymphoma clinical trials: A re-examination of enrich study data

Plasma protein ADAMTS8 as a minimally invasive favorable prognostic biomarker in mantle cell lymphoma

Risk of bleeding in 15,495 patients with myeloproliferative neoplasms by treatment type and thrombotic history

Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich

Incidence of Infections and Survival Outcomes in Patients with Multiple Myeloma and Chronic Lymphocytic Leukemia in Sweden: A Nationwide Population-Based Study of More Than 15,000 Patients

Survival in Mantle Cell Lymphoma Patients with a Second Primary Malignancy

Acalabrutinib and Rituximab in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma Including a Matched Population-Based External Comparator- the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) Phase II Trial

Zilovertamab Vedotin Monotherapy for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort a of the Multicenter, Open-Label, Phase 2 Waveline-006 Study

Plasma Proteomic Profiling Identifies Prognostic Biomarkers in Mantle Cell Lymphoma

Rule-Based Machine Learning Analysis of the Blood Proteome Identifies MCL Patients with High Risk of Early Disease Progression

Timing of Disease Progression and Impact on Survival in Mantle Cell Lymphoma: A Novel Illness-Death Model Study from the Swedish Mclcomplete Project

Zilovertamab Vedotin in Combination with Nemtabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort C of the Open-Label, Phase 2 Waveline-006 Study

Plasma Proteomics Differentiates between Patients with B-Cell Lymphomas

Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study

Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase Ib-II Trial

Treatment-Related Circulatory Diseases and Mortality in Hodgkin Lymphoma Patients Using Multi-State Modelling and Relative Survival

Reproduktiv Patterns Among Non-Hodgkin Lymphoma Survivors By Subtype in Sweden, Denmark and Norway

Late Effects after Treatment in Mantle Cell Lymphoma: No Difference By Intensity of First-Line Regimens with or without Autologous Stem Cell Transplantation

Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - Data from the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase I Trial: Stopping Treatment in Molecular Remission Is Feasible

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only